Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

EKF Diagnostics Acquires Selah Genomics and DiaSpect Medical

By Labmedica International staff writers
Posted on 30 Apr 2014
Print article
EKF Diagnostics (Cardiff, Wales, UK), a global in vitro diagnostics business, has acquired Selah Genomics, Inc. and DiaSpect Medical AB, enhancing its hemoglobin analysis and personalized medicine capabilities. Sweden based DiaSpect manufactures desktop hemoglobin analyzers, while Selah, of South Carolina (USA), is a service provider that supplies molecular diagnostics tests for the development of personalized medicine.

The integration of DiaSpect’s product line into the existing portfolio of EKF hemaglobin analyzers will enable the provision of an analyzer to meet any need. The patented DiaSpect Hb-system provides instant results from one drop of whole blood. It is suitable for use in dry or humid conditions, and the broad-spectrum photometer together with the reagent-free cuvette is reliable and cost-effective. This desktop device will join the point of care (POC) Hemo Control (Hemo Point H2 in the USA) and the hand-held, portable STAT-Site hemoglobin analyzer.

The acquisition of Selah Genomics enables EKF to extend its molecular diagnostics offering to support healthcare providers and the pharmaceutical industry with advanced molecular and genomic diagnostic services. The easy-to-use service provides doctors with a sample kit, and once they have obtained a swab from the patient, it is simply sealed and posted back for analysis. Resulting data can be used to develop personalized treatment plans.

Combined with the recent acquisition of Separation Technology, Inc. this purchase has strengthened EKF’s product and services offering, positioning EKF at the forefront of the POC hematology testing provision. EKF now offers a comprehensive and cost-effective product range, as well as being able to participate in personalized medicine; an area which is quickly becoming important in the in vitro diagnostic (IVD) industry.

Julian Baines, CEO of EKF, commented, “These acquisitions provide us with a huge opportunity to establish ourselves as a leading global player in point of care hemoglobin testing and to consider our position in molecular diagnostics and personalized medicine, an area which we consider to be one of the most exciting in diagnostics.”

EKF Diagnostics Holdings plc which includes the EKF Diagnostics, EKF Molecular, Stanbio Laboratory, Separation Technology Inc, DiaSpect, and Selah Genomics brands specializes in the development, production, and worldwide distribution of point-of-care blood analyzers for use in the detection and management of diabetes, anemia, lactate and kidney related diseases. Its new molecular division focuses on molecular and companion diagnostics.

Related Links:

EKF Diagnostics



Print article

Channels

Clinical Chemistry

view channel

New Approach Improves Identification of Women at High Risk of Preeclampsia

A new meta-analysis examining 92 cohort studies involving over 25 million pregnancies has provided an unprecedented understanding of risk factors for preeclampsia—some risk factors being strong enough to warrant that a pregnant woman starts on prophylactic treatment with acetylsalicylic acid (ASA) when she has only one.... Read more

Genetic Tests

view channel

Patterns of MicroRNA Expression Distinguish Patients with Asthma and Allergic Rhinitis

Subsets of circulating micro RNAs (miRNAs) are uniquely expressed in asthmatic patients and in patients with allergic rhinitis (AR) and have potential for use as noninvasive biomarkers to diagnose and characterize these diseases. MicroRNAs are a class of about 20 nucleotides-long RNA fragments that block gene expression... Read more

Pathology

view channel

Liver Cancer May Be Diagnosed from Altered Sugar Metabolism

Altered gene expression that causes cancerous cells to metabolize fructose differently from healthy cells could be a significant new biomarker for diagnosing liver cancer. Dietary fructose is primarily metabolized in the liver and it has now been demonstrated that, compared with normal hepatocytes, hepatocellular carcinoma... Read more

Lab Tech.

view channel

Method Preserves Microfluidic Devices for HIV Monitoring in Developing Countries

Microfluidic devices with immunochemistry have broad applications in chemotherapy monitoring, transplant patient monitoring, and especially in monitoring the efficacy of antiretroviral therapy. Providing vital health care services to people in developing countries without reliable electricity, refrigeration and state-of-the-art... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.